Registration Dossier

Data platform availability banner - registered substances factsheets

Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.

The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.

Diss Factsheets

Toxicological information

Repeated dose toxicity: oral

Currently viewing:

Administrative data

Endpoint:
short-term repeated dose toxicity: oral
Type of information:
experimental study
Adequacy of study:
other information
Reliability:
3 (not reliable)
Rationale for reliability incl. deficiencies:
other: Documentation insufficient for assessment (small number of animals, treatment time rather short, only the max dose given, only high dose results reported Thus no dose-effect relationship can be derived).

Data source

Referenceopen allclose all

Title:
No information
Author:
Giddings M. et al. (1994). Evaluation of risks to health from environmental exposure in Canada. Environm. Carcino.Ecotox. Revs. C12, 517-525
Title:
No information
Author:
Rimmington C and G Ziegler (1963). Experimental porphyria in rats induced by chlorinated benzenes. Biochem. Pharmacol. 12, 1387-1397

Materials and methods

Principles of method if other than guideline:
Method: other: 3 rats, gradually increased dosing, only maximum dose reported, urinary porphyrins, porphobilinogen and delta- aminolaevulic acid were determined in 24-hours samples, liver examined Controls: solvent, Allylisopropylacetamid, Sed
GLP compliance:
no

Test material

Constituent 1
Chemical structure
Reference substance name:
1,2,3-trichlorobenzene
EC Number:
201-757-1
EC Name:
1,2,3-trichlorobenzene
Cas Number:
87-61-6
Molecular formula:
C6H3Cl3
IUPAC Name:
1,2,3-trichlorobenzene
Details on test material:
IUCLID4 Test substance: other TS: 1,2,3-trichlorobenzene, no data on purity

Test animals

Species:
rat
Strain:
not specified
Sex:
male

Administration / exposure

Route of administration:
oral: gavage
Duration of treatment / exposure:
7 days
Frequency of treatment:
daily
Doses / concentrations
Remarks:
Doses / Concentrations:
up to 785 mg/kg bw (max. dose) dissolved in 1% celofas
Basis:
Control animals:
yes
Details on study design:
Post-exposure period: no

Results and discussion

Target system / organ toxicity

Critical effects observed:
not specified

Any other information on results incl. tables

RS-Freetext:
Urinary porphyrins and porphyrin percursers were the first apparent sign  of intoxication:
max dose: 785 mg/kg bw versus solvent control:
36.59 versus 4.3-6.8 µg/day Coproporphyrin, 
0.72 versus 0.1-0.3 µg/day uroporphyrin, 
57.38  versus 2.5-6.5 µg/day porphobilinogen, 
36.26 versus 38.7-51.6 µg/day delta-aminolaevulic acid
clinical signs:
weight loss, extreme weakness, ataxia, clonic contractions, slight tremor
liver examination:
degeneration of individual liver cells without actual necrosis, or small  areas showing focal necrosis in the central midzonal and periportal region

Applicant's summary and conclusion